Therefore, the aim of this study was to analyze the direct relationship of ANA presence before and after the administration of IFX or ADA with the appearance of ADrA in order to evaluate the usefulness of ANA measurement for predicting treatment inefficacy and secondary failure in RA patients. The gene discussed is BTG3; the disease is rheumatoid arthritis.